The New England Healthcare Executive Network will host a panel of leaders to discuss the topic of mergers and acquisitions in the medical device industry. For the third consecutive year, DeviceTalks has partnered with the New England Healthcare Executive Network at DeviceTalks Boston. At DeviceTalks Boston 2019, NE Healthcare Executive Network’s member meeting will offer […]
Histogenics to merge with Ocugen
Histogenics (NSDQ:HSGX) said yesterday that it inked a definitive merger agreement with Ocugen through which both companies will combine into a single publicly-traded, clinical-stage biopharmaceutical company. The combined entity will operate under the Ocugen name, the companies said. As part of the deal, Ocugen’s shareholders will become the majority owners of Histogenics outstanding common stock upon […]
Pacira to acquire Myoscience in $220m deal
Pacira Pharmaceuticals (NSDQ:PCRX) said today that it has signed a deal to acquire Myoscience and its pain relief device for up to $220 million. Myoscience’s iovera system is designed to safely freeze nerves while protecting surrounding tissue. As part of the deal that is slated to close by early April, Pacira plans to incorporate the iovera […]
ResMed closes $225m Propeller Health purchase
ResMed (NYSE:RMD) said yesterday that it completed its $225 million acquisition of Propeller Health and its digital medicine platform. Lead by CEO David Van Sickle, Propeller will continue to operate as a standalone business within ResMed’s respiratory care portfolio, the companies reported. ResMed first announced the deal in December, explaining that Propeller’s products for people with […]
Del. supremes uphold Fresenius bailout on Akorn buy
Delaware’s Supreme Court ruled last week to uphold a decision by the state’s Chancery Court that Fresenius (ETR:FRE) could walk away from its $4 billion merger with Akorn (NSDQ:AKRX). The initial deal was designed to help Fresenius move into new therapeutic areas and dosage forms, including eye drugs, ear drops, nasal sprays and respiratory drugs. But Fresenius abandoned the […]
ResMed puts $225m on the table for Propeller Health
ResMed (NYSE:RMD) said today that it inked a deal to acquire Propeller Health and its digital medicine platform for $225 million in cash. Propeller Health, which sells small sensors that attach to inhalers and track medication use, will operate as a standalone business under ResMed’s respiratory care portfolio. ResMed reported that Propeller’s products for people […]
Medtronic inks deal to acquire nutrition tech group Nutrino Health
Medtronic (NYSE:MDT) said today that it inked a deal to acquire nutrition tech company Nutrino Health for an undisclosed amount, with plans on integrating it into the company’s diabetes division. Nutrino Health provides nutrition-related data services, analytics and technologies, Fridley, Minn.-based Medtronic said. The company added that it plans to integrate Nutrino’s food analysis infrastructure, nutrition […]
Boston Scientific puts $4B on the table for BTG’s interventional portfolio
Boston Scientific (NYSE:BSX) said today that it agreed to offer $4.24 billion to acquire British medical device maker BTG (LON:BTG) and its portfolio of interventional drug-device therapies. The Marlborough, Mass.-based company said that its acquisition of BTG will augment Boston Scientific’s capabilities in the treatment of cancer and pulmonary embolism. “We are confident that the addition of these therapies […]
Purdue acquires non-opioid painkiller with SpineThera purchase
Purdue Pharma announced today that it acquired SpineThera and a dexamethasone epidural product designed to treat low back pain. SpineThera’s SX600 therapy features tiny, biodegradable microspheres which enable sustained-release of dexamethasone. “We are pleased to partner with SpineThera to support further development of its novel steroid product for epidural injection for patients who suffer from […]
Fresenius cleared to jilt Akorn, court rules
The Delaware Chancery Court ruled this week that it can’t force Fresenius (ETR:FRE) to follow through with its $4.75 billion merger with Akorn (NSDQ:AKRX). The deal was designed to help Fresenius move into new dosage forms and therapeutic areas, including ophthalmic drugs, ear drops, nasal sprays and respiratory drugs. But Fresenius walked away from the deal in April, […]
- 1
- 2
- 3
- …
- 11
- Next Page »
Drug Delivery Business News
@DrugDeliveryNow
LinkedIn